CORONA Remedies Statistics
Total Valuation
CORONA Remedies has a market cap or net worth of INR 136.80 billion. The enterprise value is 136.96 billion.
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jun 19, 2026 |
Share Statistics
CORONA Remedies has 61.16 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 61.16M |
| Shares Outstanding | 61.16M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 64.00% |
| Owned by Institutions (%) | 11.78% |
| Float | 16.34M |
Valuation Ratios
The trailing PE ratio is 66.08 and the forward PE ratio is 49.97. CORONA Remedies's PEG ratio is 1.72.
| PE Ratio | 66.08 |
| Forward PE | 49.97 |
| PS Ratio | 8.85 |
| PB Ratio | 17.14 |
| P/TBV Ratio | 24.72 |
| P/FCF Ratio | 226.88 |
| P/OCF Ratio | 60.32 |
| PEG Ratio | 1.72 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 41.24, with an EV/FCF ratio of 227.15.
| EV / Earnings | 66.73 |
| EV / Sales | 8.86 |
| EV / EBITDA | 41.24 |
| EV / EBIT | 48.10 |
| EV / FCF | 227.15 |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.42 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 1.89 |
| Interest Coverage | 34.89 |
Financial Efficiency
Return on equity (ROE) is 28.27% and return on invested capital (ROIC) is 25.70%.
| Return on Equity (ROE) | 28.27% |
| Return on Assets (ROA) | 16.12% |
| Return on Invested Capital (ROIC) | 25.70% |
| Return on Capital Employed (ROCE) | 31.38% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 3.03M |
| Profits Per Employee | 401,747 |
| Employee Count | 5,153 |
| Asset Turnover | 1.40 |
| Inventory Turnover | 2.13 |
Taxes
In the past 12 months, CORONA Remedies has paid 640.40 million in taxes.
| Income Tax | 640.40M |
| Effective Tax Rate | 23.63% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2,170.18 |
| 200-Day Moving Average | 1,886.33 |
| Relative Strength Index (RSI) | 48.84 |
| Average Volume (20 Days) | 61,994 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CORONA Remedies had revenue of INR 15.59 billion and earned 2.07 billion in profits. Earnings per share was 33.85.
| Revenue | 15.59B |
| Gross Profit | 12.64B |
| Operating Income | 2.87B |
| Pretax Income | 2.71B |
| Net Income | 2.07B |
| EBITDA | 3.31B |
| EBIT | 2.87B |
| Earnings Per Share (EPS) | 33.85 |
Full Income Statement Balance Sheet
The company has 987.90 million in cash and 1.15 billion in debt, with a net cash position of -163.70 million or -2.68 per share.
| Cash & Cash Equivalents | 987.90M |
| Total Debt | 1.15B |
| Net Cash | -163.70M |
| Net Cash Per Share | -2.68 |
| Equity (Book Value) | 8.05B |
| Book Value Per Share | 131.63 |
| Working Capital | 1.41B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 2.29 billion and capital expenditures -1.68 billion, giving a free cash flow of 608.20 million.
| Operating Cash Flow | 2.29B |
| Capital Expenditures | -1.68B |
| Depreciation & Amortization | 443.40M |
| Net Borrowing | 520.10M |
| Free Cash Flow | 608.20M |
| FCF Per Share | 9.94 |
Full Cash Flow Statement Margins
Gross margin is 81.04%, with operating and profit margins of 18.39% and 13.28%.
| Gross Margin | 81.04% |
| Operating Margin | 18.39% |
| Pretax Margin | 17.39% |
| Profit Margin | 13.28% |
| EBITDA Margin | 21.24% |
| EBIT Margin | 18.39% |
| FCF Margin | 3.90% |
Dividends & Yields
This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.45%.
| Dividend Per Share | 10.00 |
| Dividend Yield | 0.45% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 29.54% |
| FCF Payout Ratio | 100.56% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 0.42% |
| Earnings Yield | 1.51% |
| FCF Yield | 0.44% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for CORONA Remedies is 2,494.67, which is 11.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 2,494.67 |
| Price Target Difference | 11.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 18.03% |
| EPS Growth Forecast (3Y) | 26.58% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |